TABLE 1

Baseline Characteristics and Results for Cohort A

		Preoperative data				⁶⁸Ga-THP-PSMA		Postoperative data
Patient	Age (y)	Gleason score (GS)	PSA	Clinical T stage	MRI	Prostate SUV_max	Nodal SUV_max	GS	Pathologic stage	PSMA IHC
1	71	3 + 5 = 8	10.3	T3	PIRADS 4	5.6		4 + 3 = 7	T3bN1^*	3+
2	64	3 + 4 = 7	6.2	T2a/b	PIRADS 5			3 + 4 = 7	T2cNx	2+
3	55	4 + 3 = 7	9.6	T1c	PIRADS 2	2.5		4 + 3 = 7	T3aN0	3+
4	65	3 + 4 = 7	5.4	T1	PIRADS 4	4.0		3 + 4 = 7	T2cNx	3+
5	71	3 + 4 = 7	3.2	T2b	PIRADS 5	2.4		4 + 3 = 7	T3aNx	3+
6	54	5 + 5 = 10	9	T2b	PIRADS 5			4 + 5 = 9	T3aN1^†	1+
7	46	4 + 4 = 8	10.6	T3a	PIRADS 5	7.1		4 + 5 = 9	T3aN0	3+
8	58	4 + 4 = 8	8	T2c	Not performed	9.2	18.4^‡	4 + 5 = 9	T3bN0	3+

↵* 0.6 mm in 1 lymph node.
↵† 0.1 mm in 1 lymph node.
↵‡ Confirmed as true-positive on follow-up, with sampling error resulting in pathologic N0 staging.
IHC = immunohistochemistry; PIRADS = Prostate Imaging Reporting and Data System, v2.